Dai Fukumura
Overview
Explore the profile of Dai Fukumura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
17015
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomes-Santos I, Kumar A, Hausmann F, Meyer M, Shiferaw S, Amoozgar Z, et al.
Front Immunol
. 2024 Mar;
15():1339232.
PMID: 38495879
Introduction: Exercise is recommended as an adjunct therapy in cancer, but its effectiveness varies. Our hypothesis is that the benefit depends on the exercise intensity. Methods: We subjected mice to...
2.
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, et al.
Cancer Immunol Res
. 2024 Jan;
12(4):400-412.
PMID: 38260999
Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti-programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary...
3.
Jain R, Krishnan S, Lee S, Amoozgar Z, Subudhi S, Kumar A, et al.
Res Sq
. 2024 Jan;
PMID: 38234841
Wnt signaling plays a critical role in the progression and treatment outcome of glioblastoma (GBM). Here, we identified WNT7b as a heretofore unknown mechanism of resistance to immune checkpoint inhibition...
4.
Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36898734
Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. This...
5.
Boucher Y, Posada J, Subudhi S, Kumar A, Rosario S, Gu L, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1605-1619.
PMID: 36749873
Purpose: Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients with locally advanced pancreatic cancer...
6.
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, et al.
bioRxiv
. 2023 Feb;
PMID: 36747853
Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Anti-PD-L1 immunotherapy combined with gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary tract cancers, but responses are seen only...
7.
Katagiri W, Yokomizo S, Ishizuka T, Yamashita K, Kopp T, Roessing M, et al.
FASEB J
. 2022 Sep;
36(10):e22521.
PMID: 36052742
Immunotherapy, including immune checkpoint inhibitors, has revolutionized cancer treatment, but only a minor fraction of patients shows durable responses. A new approach to overcome this limitation is yet to be...
8.
Ho W, Pittet M, Fukumura D, Jain R
Cancer Cell
. 2022 Jun;
40(7):701-702.
PMID: 35714604
No abstract available.
9.
Martin J, Lanning R, Chauhan V, Martin M, Mousa A, Kamoun W, et al.
Clin Cancer Res
. 2022 May;
28(14):3076-3090.
PMID: 35584239
Purpose: The abnormal function of tumor blood vessels causes tissue hypoxia, promoting disease progression and treatment resistance. Although tumor microenvironment normalization strategies can alleviate hypoxia globally, how local oxygen levels...
10.
Agrud A, Subburaju S, Goel P, Ren J, Kumar A, Caldarone B, et al.
Sci Rep
. 2022 Mar;
12(1):4922.
PMID: 35318369
Our recent studies uncovered a novel GABA signaling pathway in embryonic forebrain endothelial cells that works independently from neuronal GABA signaling and revealed that disruptions in endothelial GABA receptor-GABA signaling...